In yesterday’s Wall Street session, Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares traded at $104.14, up 0.68% from the previous session.
As of this writing, 26 analysts cover Neurocrine Biosciences Inc. (NASDAQ:NBIX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $150.00 and a low of $95.00, we find $125.00. Given the previous closing price of $103.44, this indicates a potential upside of 20.84 percent. NBIX stock price is now 8.70% away from the 50-day moving average and -1.19% away from the 200-day moving average. The market capitalization of the company currently stands at $10.01B.
There are 7 analysts who have given it a hold rating, whereas 16 have given it a buy rating. Brokers who have rated the stock have averaged $126.08 as their price target over the next twelve months.
With the price target enhanced from $115 to $125, SVB Securities Upgraded its rating from Market Perform to Outperform for Neurocrine Biosciences Inc. (NASDAQ: NBIX).
In other news, Cooke Julie, Chief Human Resources Officer sold 11,397 shares of the company’s stock on May 01. The stock was sold for $1,184,049 at an average price of $103.89. Upon completion of the transaction, the Chief Human Resources Officer now directly owns 16,169 shares in the company, valued at $1.68 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, Director RASTETTER WILLIAM H sold 4,300 shares of the business’s stock. A total of $436,135 was realized by selling the stock at an average price of $101.43. This leaves the insider owning 42,785 shares of the company worth $4.46 million. Insiders disposed of 476,653 shares of company stock worth roughly $49.64 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NBIX stock. A new stake in Neurocrine Biosciences Inc. shares was purchased by BRAIDWELL LP during the first quarter worth $79,855,000. LOGOS GLOBAL MANAGEMENT LP invested $20,828,000 in shares of NBIX during the first quarter. In the first quarter, LOOMIS SAYLES & CO L P acquired a new stake in Neurocrine Biosciences Inc. valued at approximately $16,975,000. PROSIGHT MANAGEMENT, LP acquired a new stake in NBIX for approximately $8,331,000. BRIDGEWATER ASSOCIATES, LP purchased a new stake in NBIX valued at around $6,166,000 in the second quarter.
Wednesday morning saw Neurocrine Biosciences Inc. (NASDAQ: NBIX) opened at $103.61. During the past 12 months, Neurocrine Biosciences Inc. has had a low of $89.04 and a high of $129.29. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 3.80, and a quick ratio of 3.70. According to the stock market information, the enterprise value for the company is $9.46B, which is based on a 170.72 price-to-earnings ratio, a 7.17 price-to-earnings-growth ratio, and a beta of 0.47. The fifty day moving average price for NBIX is $96.01 and a two-hundred day moving average price translates $105.36 for the stock.
According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.95, beating analysts’ expectations of $0.78 by 0.17. This compares to -$0.18 EPS in the same period last year. The net profit margin was 4.00% and return on equity was 4.00% for NBIX. The company reported revenue of $452.7 million for the quarter, compared to $378.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 19.7 percent. For the current quarter, analysts expect NBIX to generate $472.66M in revenue.
